Search clinical trials for: Sarcomere Mutations

Total 1212 results

AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
NYU Langone Health
Novartis

Withdrawn

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

Glioma

United States
GlaxoSmithKline

Withdrawn

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Cancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
GlaxoSmithKline

Withdrawn

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors

Solid Tumours
Hadassah Medical Organization

Completed

Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)

Cystic Fibrosis

Israel
Hadassah Medical Organization

Terminated

Development of Resistance Mutations in Pregnant HIV-positive (+) Women Following Perinatal Antiretroviral Therapy in Israel

HIV Infections

Israel
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Breast Cancer | brca1 Mutation Carrier | brca2 Mutation Carrier

United States
Betta Pharmaceuticals Co., Ltd.

Unknown

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer (CHALLENGE)

Plasma EGFR Mutation-positive Lung Cancer

China
GlaxoSmithKline

Completed

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Cancer

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Cancer

United States, Australia, United Kingdom
Sheba Medical Center

Withdrawn

Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission

Familial Mediterranean Fever

Israel
Array BioPharma

Completed

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Metastatic Colorectal Cancer

United States, Australia, Belgium, Canada, France, Israel, Italy, Netherlands, Singapore, Spain
Association des Gastroentérologues Oncologues
Pitié-Salpêtrière Hospital; Hôpital Européen George Pompidou, APHP, Paris,... and other collaborators

Unknown

RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO) (RASINTRO)

Metastatic Colorectal Cancer
University of Florida
Food and Drug Administration (FDA); FDA Office of Orphan Products Development

Completed

Phase III Trial of Coenzyme Q10 in Mitochondrial Disease

Mitochondrial Diseases

United States, Canada
Hoffmann-La Roche

Completed

ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations

Non-Squamous Non-Small Cell Lung Cancer

Spain
British Columbia Cancer Agency
Insight Genetics

Completed

Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients (PCRTALK)

Nonsmall Cell Lung Cancer

Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer

Breast Cancer

United States
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Solid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
European Organisation for Research and Treatment...

Unknown

Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

France, Belgium, Portugal
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Breast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier

United States
Astellas Pharma Global Development, Inc.

Withdrawn

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Subjects With NSCLC With an EGFR Activating Mutation
National Institute of Allergy and Infectious Diseases...

Completed

Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research

Hemoglobin Mutations | Erythrocyte Variants

United States
National Human Genome Research Institute (NHGRI)

Completed

Molecular Analysis of Microphthalmia/Anophthalmia

Anophthalmos

United States
National Institute of Environmental Health Sciences...

Completed

Estrogen Receptor Gene Mutations

Hormones | Mutations

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

Healthy | Rheumatoid Arthritis | Pulmonary Fibrosis

United States
National Human Genome Research Institute (NHGRI)

Completed

Genetic Analysis of Oculocerebrorenal Syndrome of Lowe

Lowe Syndrome

United States
Hospital General de Mexico

Unknown

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

Acute Myeloid Leukemia (AML)

Mexico
Tanta University

Unknown

Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer

Thrombosis

Egypt
VA Connecticut Healthcare System

Completed

Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations

Erythromelalgia

United States
ViiV Healthcare

Completed

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Italy
Genentech, Inc.

Terminated

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Malignant Melanoma

United States
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia

Leukemia
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Head and Neck Cancer

Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598

Lung Cancer
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia

Leukemia
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803

Prostate Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Study of Bone Marrow Samples From Patients With Acute Leukemia

Leukemia
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms

Lymphoma
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial

Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

Lung Cancer
AstraZeneca

Completed

Asia Pacific and Russia Diagnostic Study for EGFR Testing (IGNITE)

EGFR Mutation Status in aNSCLC Patients

Korea, Republic of, Russian Federation, Malaysia, China, Australia, Taiwan, Thailand, Indonesia, Singapore
University of Aarhus

Unknown

Prevalence and Significance of Mutations in Genes Encoding NaPi-co-transporters in the Development of CAVD

Aortic Stenosis | Aortic Valve Calcification

Denmark
National Cancer Institute (NCI)

Completed

Phase II ABT-888 With Cyclophosphamide

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Triple-Negative Breast Cancer | Serous Carcinoma Cancer

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Leukemia
Spanish Lung Cancer Group

Completed

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone (GOAL)

Non Small Cell Lung Cancer

Spain
Hoffmann-La Roche

Completed

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations (BIOTEC)

Carcinoma，Non-Small-Cell Lung

Romania
Rigshospitalet, Denmark

Completed

MRI on Persons With Mutations in POMT2 Gene (LGMD2N)

Limb-girdle Muscular Dystrophy

Denmark
Georgetown University
National Cancer Institute (NCI)

Completed

Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations

Breast Cancer
Boehringer Ingelheim

Completed

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Carcinoma, Non-Small-Cell Lung

Canada

Search clinical trials for: Sarcomere Mutations

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations